Lipocine (NASDAQ:LPCN)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Friday. They presently have a $10.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 189.86% from the stock’s previous close.

LPCN has been the topic of a number of other reports. Roth Capital set a $38.00 target price on shares of Lipocine and gave the stock a “buy” rating in a report on Thursday, August 10th. ValuEngine downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th.

Shares of Lipocine (LPCN) opened at $3.45 on Friday. Lipocine has a fifty-two week low of $3.25 and a fifty-two week high of $5.33.

Several large investors have recently made changes to their positions in LPCN. Carlson Capital L P purchased a new stake in shares of Lipocine in the 4th quarter valued at approximately $2,970,000. JPMorgan Chase & Co. purchased a new stake in shares of Lipocine in the 3rd quarter valued at approximately $935,000. Vanguard Group Inc. increased its position in shares of Lipocine by 39.7% in the 2nd quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock valued at $2,195,000 after purchasing an additional 155,110 shares during the last quarter. DRW Securities LLC purchased a new stake in shares of Lipocine in the 2nd quarter valued at approximately $443,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Lipocine by 73.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 271,272 shares of the specialty pharmaceutical company’s stock valued at $3,508,000 after purchasing an additional 114,448 shares during the last quarter. 22.06% of the stock is currently owned by institutional investors.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/08/hc-wainwright-reaffirms-buy-rating-for-lipocine-lpcn.html.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Receive News & Ratings for Lipocine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc and related companies with MarketBeat.com's FREE daily email newsletter.